The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1301
CRP and Statins for Primary Prevention of Coronary Artery Disease
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Modestly elevated C-reactive protein (CRP) concentrations have been associated with an increased risk of coronary heart disease.1 The recently published and heavily publicized results of the JUPITER trial will lead many patients to ask health care professionals whether they should have a CRP test to see if they should be taking a statin.

CRP — Inflammation is thought to play a role in the development of atherosclerosis. The cytokines that would be the most direct markers of inflammation are difficult to quantify because they are unstable in serum, but they upregulate hepatic synthesis of acute-phase reactants; these include amyloid, fibrinogen and C-reactive protein (CRP), so named because it can precipitate the C-polysaccharide of Streptococcus pneumoniae. Because CRP is stable in serum and easily measured by commercial assays, it has become the most widely used marker of inflammation. A ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: CRP and Statins for Primary Prevention of Coronary Artery Disease
Article code: 1301a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian